Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Blood (2025) 146 (Supplement 1): 670.

https://doi.org/10.1182/blood-2025-670

Published: 2025

Journal Articles

Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study

Ana Marin Niebla, Eva Gine, Mariana Bastos-Oreiro, Amanda Perez, Alba Cabirta, Fatima De la Cruz Vicente, Marta Canelo Vilaseca, Ana Jiménez Ubieto, Sonia González De Villambrosia, Ana Muntanola Prat, Eva Gonzalez Barca, Hugo Daniel Luzardo Henríquez, Eduardo Rios Herranz, Pilar Gomez Prieto, Raul Cordoba, Ana Saus Carreres, Alejandro Martin Garcia-Sancho, Ana Maria Garcia-Noblejas Moya, Carlos Grande, Pablo Prieto Martínez, Concepción Nicolás, Antonio Gutierrez, Jose Angel Hernandez Rivas, Blanca Sánchez-González, Maria Teresa Villalobos, Tomas García-Cerecedo, Rosalia Alonso Trillo, Eva Donato, Paola Villafuerte Gutiérrez, Daniel García Belmonte, Silvia Rocio Verdesoto Cozzarelli, Sandra Suarez Ordoñez, Emilia Pardal De La Mano, Amparo Avaría, Lucia Villalon Blanco, Alicia Roldán-Pérez, Juan-Manuel Sancho, Beatriz De La Cruz, Raja Prince-Eladnani, Pau Abrisqueta

Blood (2025) 146 (Supplement 1): 3592.

https://doi.org/10.1182/blood-2025-3592

Published: 2025

Journal Articles

Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group

Mariana Bastos-Oreiro, Alba Cabirta, Amanda Perez, Ana Saus Carreres, Sonia González De Villambrosia, Marta Canelo, Ana Maria Garcia-Noblejas Moya, Beatriz De La Cruz Benito, Paola Villafuerte Gutiérrez, Fatima De la Cruz Vicente, Juan Carlos Caballero, Ana Jiménez-Ubieto, Daniel García Belmonte, Ana Muntanola Prat, Eva Gonzalez Barca, Hugo Daniel Luzardo Henríquez, Eduardo Rios Herranz, Alejandro Martin Garcia-Sancho, Carlos Grande, Concepción Nicolás, Antonio Gutierrez, Marina Gomez-Llobell, Jose Angel Hernandez Rivas, Blanca Sánchez-González, Ainara Ferrero Campos, Rosalia Alonso Trillo, Eva Donato, Silvia Rocio Verdesoto Cozzarelli, Sandra Suarez Ordoñez, Emilia Pardal De La Mano, Pilar Gomez Prieto, Amparo Avaría, Lucia Villalon Blanco, Alicia Roldán-Pérez, Raul Cordoba, Juan-Manuel Sancho, Eva Gine, Víctor Navarro Garces, Pau Abrisqueta, Ana Marin Niebla

Blood (2025) 146 (Supplement 1): 3585.

https://doi.org/10.1182/blood-2025-3585

Published: 2025

Journal Articles

Plasmablastic lymphoma (PBL) comparison between europe - Latin America and validation of the PBL international prognostic index (PBL-IPI): Collaborative study of the lymphoma groups geltamo, gatla and gell

Blood (2025) 146 (Supplement 1): 899.

https://doi.org/10.1182/blood-2025-899

Published: 2025

Journal Articles

Allogeneic transplantation and frontline therapy shape survival outcomes in secondary AML: Real-world epidemiology and prognostic insights

Rosa Coll, Nuria Brey, Antonella Luciana Sturla, Jordi Viñas, Montserrat Arnan, Helena Pomares, Susana Vives, Anna Sureda Balarí, Juan-Manuel Sancho, David Gallardo

Blood (2025) 146 (Supplement 1): 6896.

https://doi.org/10.1182/blood-2025-6896

Published: 2025

Journal Articles

A phase II study of acalabrutinib in combination with R-CHOP for previously untreated transplant-ineligible mantle cell lymphoma patients in Spain (the SOUND-MCL Study)

Ana Marin Niebla, Alejandro Martin Garcia-Sancho, Jorge Castro García, Esther Álvarez García, Ángel Callejo Mellén, Juan-Manuel Sancho

Blood (2025) 146 (Supplement 1): 1838.

https://doi.org/10.1182/blood-2025-1838

Published: 2025

Journal Articles

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Blood (2025) 146 (Supplement 1): 63.

https://doi.org/10.1182/blood-2025-63

Published: 2025

Journal Articles

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Blood (2024) 144 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2024-212970

Published: 2024

Journal Articles

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Blood (2024) 144 (Supplement 1): 4478.

https://doi.org/10.1182/blood-2024-212008

Published: 2024

Journal Articles

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 3009.

https://doi.org/10.1182/blood-2024-205671

Published: 2024

Journal Articles

Profile of Inflammatory Biomarkers in Hodgkin Lymphoma. Differences between HIV-Negative and HIV-Positive Patients

Vitor Botafogo, Andrea Usas, Miriam Verdú-Bou, Miram Moreno, Gema Fernández-Rivas, Pere-Joan Cardona, Federico Fondelli, Eva Martínez-Cáceres, Maria Doladé, Ignacio Blanco, José Moltó, Gustavo Tapia, Juan-Manuel Sancho, Josep-Maria Ribera, Jose Tomas Navarro

Blood (2024) 144 (Supplement 1): 6249.

https://doi.org/10.1182/blood-2024-204572

Published: 2024

Journal Articles

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Blood (2024) 144 (Supplement 1): 4422.

https://doi.org/10.1182/blood-2024-211078

Published: 2024

Journal Articles

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Blood (2024) 144 (Supplement 1): 4403.

https://doi.org/10.1182/blood-2024-209936

Published: 2024

Journal Articles

High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1626.

https://doi.org/10.1182/blood-2024-200290

Published: 2024

Journal Articles

Immunotherapy May be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients

Blood (2024) 144 (Supplement 1): 1658.

https://doi.org/10.1182/blood-2024-207871

Published: 2024

Journal Articles

Prognostic Factors and Treatment Strategy in Patients with Hodgkin Lymphoma and HIV Infection Treated with ABVD and CART: A Retrospective Study from Spanish Group Geltamo

Maria Huguet, Aleix Méndez, Blanca Sanchez-Gonzalez, Mariana Bastos-Oreiro, Ramon Garcia-Sanz, Samuel Romero, María-Jesús Vidal-Manceñido, Antonio Gutiérrez, Paola Villafuerte Gutierrez, Ana Garcia Noblejas, Gustavo Tapia, Juan-Manuel Sancho, Josep-Maria Ribera, José-Tomás Navarro

Blood (2023) 142 (Supplement 1): 4454.

https://doi.org/10.1182/blood-2023-189756

Published: 2023

Journal Articles

Beyond MIPI: Harnessing Machine Learning and Histological Subtype for Enhanced MCL Prognostication of Survival

Blood (2023) 142 (Supplement 1): 4419.

https://doi.org/10.1182/blood-2023-179174

Published: 2023

Journal Articles

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Blood (2023) 142 (Supplement 1): 4883.

https://doi.org/10.1182/blood-2023-185858

Published: 2023

Journal Articles

Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 267.

https://doi.org/10.1182/blood-2023-186388

Published: 2023

Journal Articles

Impact of the Current Treatments on the Survival of Patients with Mantle Cell Lymphoma (MCL): A Real-Life Study on Behalf of the Spanish Group of Lymphoma (GELTAMO)

Blood (2023) 142 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2023-186101

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study

Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group

Plasmablastic lymphoma (PBL) comparison between europe - Latin America and validation of the PBL international prognostic index (PBL-IPI): Collaborative study of the lymphoma groups geltamo, gatla and gell

Allogeneic transplantation and frontline therapy shape survival outcomes in secondary AML: Real-world epidemiology and prognostic insights

A phase II study of acalabrutinib in combination with R-CHOP for previously untreated transplant-ineligible mantle cell lymphoma patients in Spain (the SOUND-MCL Study)

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Profile of Inflammatory Biomarkers in Hodgkin Lymphoma. Differences between HIV-Negative and HIV-Positive Patients

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma

Immunotherapy May be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients

Prognostic Factors and Treatment Strategy in Patients with Hodgkin Lymphoma and HIV Infection Treated with ABVD and CART: A Retrospective Study from Spanish Group Geltamo

Beyond MIPI: Harnessing Machine Learning and Histological Subtype for Enhanced MCL Prognostication of Survival

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Impact of the Current Treatments on the Survival of Patients with Mantle Cell Lymphoma (MCL): A Real-Life Study on Behalf of the Spanish Group of Lymphoma (GELTAMO)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only